MediciNova, in collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, announces plans for a multicenter phase 2b study to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy MediciNova, in collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, announces plans for a multicenter phase 2b study to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy22.10.2020LA JOLLA, California, October 22, 2020 (GLOBE NEWSWIRE) – MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Tokyo…
Messenger: Trials directed at the University of Missouri for a controversial surgery – biojoint & # 039;04.09.2018